ZonMw

Global SNAP Trial Finds Cefazolin Safer and Equally Effective as Flucloxacillin for MSSA Bloodstream Infections

- The landmark SNAP trial, involving 1,341 patients across eight countries, demonstrated cefazolin is at least as effective as flucloxacillin for MSSA bloodstream infections, with 90-day mortality of 15% versus 17%. - Cefazolin was associated with significantly fewer cases of acute kidney injury (14%) compared with flucloxacillin (20%), establishing a superior safety profile. - Researchers and clinicians now recommend cefazolin as the new first-line standard of care for most adults with methicillin-susceptible S. aureus bacteremia. - The findings, published in the New England Journal of Medicine, represent the largest randomized trial ever conducted for S. aureus bloodstream infections and challenge decades of clinical practice.